Showing 161 - 180 results of 100,163 for search '(( 5 ht decrease ) OR ( 5 ((a decrease) OR (((mean decrease) OR (teer decrease)))) ))', query time: 1.30s Refine Results
  1. 161
  2. 162
  3. 163
  4. 164
  5. 165

    Knockdown of AR expression decreases the efficiency of KSHV infection in endothelial cells. by Xing Wang (154377)

    Published 2017
    “…(g, h) Knockdown of AR and EphA2 expression decreases nuclear LANA expression in SLK cells, as determined by an immunofluorescence assay and quantitative analysis by Image J software. …”
  6. 166

    Decreasing ShcA expression enhances TGF-β-induced Smad signaling. by Baby Periyanayaki Muthusamy (838234)

    Published 2015
    “…The error bars show standard error of the mean, based on three independent experiments. Supplemental data are shown in <a href="http://www.plosbiology.org/article/info:doi/10.1371/journal.pbio.1002325#pbio.1002325.s006" target="_blank">S5 Fig</a> and <a href="http://www.plosbiology.org/article/info:doi/10.1371/journal.pbio.1002325#pbio.1002325.s001" target="_blank">S1 Data</a>.…”
  7. 167
  8. 168

    Effect of 2% HQ, 0.05% INN and 0.1% TAC on hippocampal 5-HT level and 5-HT<sub>1A /1B</sub> receptor expression. by Huali Wu (349567)

    Published 2016
    “…Each bar represents mean ± SEM (n = 6). (B) The 5-HT<sub>1A</sub> receptor in the CA1 region was detected by immunohistochemistry. …”
  9. 169
  10. 170
  11. 171
  12. 172

    5-FU induces a decrease in the total cell number in cultures of smooth muscle cells. by Marcelo de Carvalho Filgueiras (408321)

    Published 2013
    “…Quantification of the number of nuclei per field revealed that 5-FU treatment induced a decrease in cell number in all the concentrations tested (<b>G</b>). …”
  13. 173
  14. 174
  15. 175
  16. 176
  17. 177

    Design, Synthesis, and Biological Evaluation of New Peripheral 5HT<sub>2A</sub> Antagonists for Nonalcoholic Fatty Liver Disease by Minhee Kim (1592440)

    Published 2020
    “…Here, structural modifications of pimavanserin (CNS drug), a 5HT<sub>2A</sub> antagonist approved for Parkinson’s disease, led us to synthesize new peripherally acting 5HT<sub>2A</sub> antagonists. …”
  18. 178
  19. 179
  20. 180